Power your team with the highest quality, daily updated intelligence on hospitals, physicians, and other healthcare providers
The following list for the top 20 drugs by total charges accounts for nearly $46 billion in charges for the year 2019. By far, the drug with the highest charges and payments is Humira. Accounting for over 16% of total charges, Humira is used in the treatment of Rheumatoid Arthritis, Crohn's Disease, Psoriatic Arthritic (PsA,) and Plaque Psoriasis (PsO,) amongst a number of other conditions. Following Humira on the list, Stelara accounts for 7.4% of total charges and treats similar conditions including Crohn's Disease, PsA, and PsO.
Of the top 20, four drugs are related to the treatment of diabetes — Humalog, Novolog, JANUVIA, and Trulicity. Drugs treating diabetes related conditions accounted for over 13% of the charges for the list.
Definitive's Healthcare Insights are developed with data from the Definitive Healthcare platform. Want even more insights? Start a Free Trial now and get access to the highest quality data and intelligence on hospitals, physicians, and other healthcare providers.
|Rank||Drug Name||Total Charges||% of Total Charges||Total Payments||Number of Prescriptions||Explore This Dataset|
|1||Humira||$7,736,528,488||16.40%||$2,219,090,212||885,238||Explore This Profile|
|2||Stelara||$3,797,384,034||7.40%||$806,102,383||170,732||Explore This Profile|
|3||Xyrem||$3,305,836,589||6.20%||$1,989,763,166||230,430||Explore This Profile|
|4||IMBRUVICA||$3,133,845,462||5.90%||$1,103,279,716||212,886||Explore This Profile|
|5||Biktarvy||$2,292,186,280||4.30%||$851,582,566||553,182||Explore This Profile|
|6||ENBREL||$2,202,123,396||4.20%||$855,062,741||300,500||Explore This Profile|
|7||Epclusa||$2,140,540,323||4.30%||$466,000,206||67,675||Explore This Profile|
|8||Revlimid||$2,110,144,764||4.00%||$785,884,233||116,825||Explore This Profile|
|9||ELIQUIS||$2,064,957,858||3.70%||$926,955,226||2,895,868||Explore This Profile|
|10||COSENTYX||$2,034,678,975||4.00%||$413,274,132||158,203||Explore This Profile|
|11||Mavyret||$1,986,125,095||3.80%||$379,545,824||116,701||Explore This Profile|
|12||Humalog||$1,691,298,530||4.70%||$576,722,288||1,400,519||Explore This Profile|
|13||NovoLog||$1,552,356,962||2.90%||$625,447,928||1,414,108||Explore This Profile|
|14||JANUVIA||$1,488,567,450||2.90%||$657,705,407||1,782,821||Explore This Profile|
|15||Trulicity||$1,482,099,197||2.70%||$573,251,821||1,147,846||Explore This Profile|
|16||Truvada||$1,468,945,228||2.70%||$462,043,822||564,050||Explore This Profile|
|17||Genvoya||$1,459,947,241||2.70%||$548,122,043||358,087||Explore This Profile|
|18||Xarelto||$1,437,444,363||2.70%||$589,426,859||1,819,252||Explore This Profile|
|19||XIFAXAN||$1,296,023,157||2.40%||$310,757,297||456,690||Explore This Profile|
|20||INVEGA SUSTENNA||$1,275,256,664||2.40%||$455,277,476||350,751||Explore This Profile|
Fig 1 Data from Definitive Healthcare based on All-Payor Commercial Claims analytics from CY 2019.